Axsome Therapeutics (AXSM) Stock Analysis & AI Equity Report
Axsome Therapeutics (AXSM) overview
Axsome Therapeutics (AXSM) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 638m and operating profit of USD -167m; the year-end share price was 182.64 USD and market capitalisation was USD 9,293m. Axsome Therapeutics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Axsome Therapeutics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Axsome Therapeutics
Axsome Therapeutics develops and commercializes medicines for central nervous system conditions. Its approved products are AUVELITY for major depressive disorder, SUNOSI for excessive daytime sleepiness associated with obstructive sleep apnea or narcolepsy, and SYMBRAVO for acute migraine treatment in adults. The company also develops investigational therapies for neurological and psychiatric conditions, including Alzheimer’s disease agitation, smoking cessation, ADHD, binge eating disorder, narcolepsy, fibromyalgia and epilepsy.
Generate the Axsome Therapeutics report
Axsome Therapeutics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Axsome Therapeutics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Axsome Therapeutics
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.